Food and Drug Administration approved eflornithine (IWILFIN, USWM, LLC) to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy.

This represents the first FDA approval of a therapy intended to reduce the risk of relapse in pediatric patients with HRNB. Read More. 

View full prescribing information for IWILFIN.